Abuse-deterrent dosage forms
AssigneePurdue Pharma L.P.
InventorsDebora L. Guido, Haiyong Huang
Life of this patent
Estimating the term…
Abstract
Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.
Claims21
An abuse-deterrent dosage form comprising an active agent susceptible to abuse and a tonicity-increasing agent, wherein the tonicity-increasing agent is in an effective amount to provide a hypertonic solution, suspension or gel of the active agent upon contact of the dosage form with from 2 ml to 5 ml of a solvent, and an osmolality the hypertonic solution, suspension or gel is from about 380 mOsmol/L to about 10000 mOsmol/L and is sufficiently hypertonic to deter abuse.
An abuse-deterrent oral dosage form comprising an active agent susceptible to abuse and a tonicity-increasing agent, wherein the tonicity-increasing agent is in an effective amount to provide a hypertonic solution, suspension or gel of the active agent upon contact of the crushed dosage form with saliva and/or oral mucosal membrane of a mammal.
21-27. (canceled)
Dependencies are inferred from the claim text.